Please ensure Javascript is enabled for purposes of website accessibility

Why Coronavirus News Sent OPKO Health's Shares Soaring 10.8% Today

By Todd Campbell - Mar 4, 2020 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The U.S. government has told Opko's BioReference Labs it can apply for approval of a COVID-19 test.

What happened

Shares of OPKO Health (OPK 2.27%) surged 10.8% on Wednesday after the U.S. Centers for Disease Control and Prevention (CDC) said it could file for approval of a test for the COVID-19 coronavirus.

So what

Over 90,000 cases of the virus have been identified in more than 70 locations, including the United States. 

Test tubes in a lab.

Image source: Getty Images.

COVID-19 can cause life-threatening respiratory illness, including pneumonia, particularly in people with compromised immune systems. Production of testing kits for the virus has lagged demand, creating a bottleneck that the CDC hopes to address by encouraging private healthcare companies, including OPKO Health's BioReference Labs, to develop their own tests.

On March 4, BioReference Labs reported that, following a discussion with the CDC, it's "working expeditiously to identify the best path forward to develop and offer a test that will yield high quality and accurate results."  

Now what

OPKO Health acquired BioReference Labs for $1.47 billion in 2015, and the specialty lab unit accounts for most of OPKO's revenue. In the third quarter, OPKO reported revenue of $228.8 million. Services, including lab unit revenue, represented $181.1 million of that amount.

Given the growing need for testing kits, there could be an opportunity for lab revenue to increase. That would be welcomed by investors because OPKO Health's revenue has been sliding, and it's losing money. In Q3, sales were down 8% and the company's loss per share worsened to $0.11 from $0.05 in the same quarter in the year prior.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$2.70 (2.27%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.